<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: statements under", fill: "#5218fa"},
{source: "2: statements under", target: "2: serve as cautionary statements within", fill: "#5218fa"},
{source: "2: serve as cautionary statements within", target: "2: Private Securities Litigation Reform Act ", fill: "#5218fa"},
{source: "2: statements under", target: "4: in the United States ", fill: "#f0e68c"},
{source: "4: in the United States ", target: "4: internationally", fill: "#f0e68c"},
{source: "4: internationally", target: "4: dependent", fill: "#f0e68c"},
{source: "4: dependent", target: "4: health care", fill: "#f0e68c"},
{source: "4: health care", target: "4: facilities", fill: "#f0e68c"},
{source: "4: facilities", target: "4: reimbursement rates", fill: "#f0e68c"},
{source: "4: reimbursement rates", target: "4: products from private", fill: "#f0e68c"},
{source: "4: products from private", target: "4: governmental", fill: "#f0e68c"},
{source: "4: governmental", target: "4: thirdparty", fill: "#f0e68c"},
{source: "4: thirdparty", target: "4: payments from consumers", fill: "#f0e68c"},
{source: "4: in the United States ", target: "9: Reimbursement ", fill: "#e34234"},
{source: "9: Reimbursement ", target: "9: international", fill: "#e34234"},
{source: "9: international", target: "9: significantly", fill: "#e34234"},
{source: "9: significantly", target: "9: government", fill: "#e34234"},
{source: "9: Reimbursement ", target: "12: Increasing ", fill: "#b0e0e6"},
{source: "12: Increasing ", target: "12: GreenLight ", fill: "#b0e0e6"},
{source: "12: GreenLight ", target: "12: laser system", fill: "#b0e0e6"},
{source: "12: laser system", target: "12: procedure could", fill: "#b0e0e6"},
{source: "12: procedure could", target: "12: hindered by", fill: "#b0e0e6"},
{source: "12: hindered by", target: "12: ongoing efforts", fill: "#b0e0e6"},
{source: "12: ongoing efforts", target: "12: health care", fill: "#b0e0e6"},
{source: "12: health care", target: "12: United States ", fill: "#b0e0e6"},
{source: "12: United States ", target: "12: Medicare Medicaid ", fill: "#b0e0e6"},
{source: "12: Medicare Medicaid ", target: "12: private healthcare", fill: "#b0e0e6"},
{source: "12: private healthcare", target: "12: managed care", fill: "#b0e0e6"},
{source: "12: managed care", target: "12: key international markets such", fill: "#b0e0e6"},
{source: "12: key international markets such", target: "12: European Union and the AsiaPacific ", fill: "#b0e0e6"},
{source: "12: European Union and the AsiaPacific ", target: "12: contain healthcare", fill: "#b0e0e6"},
{source: "12: contain healthcare", target: "12: through stricter coverage criteria price regulation", fill: "#b0e0e6"},
{source: "12: through stricter coverage criteria price regulation", target: "12: health care services disposable medical", fill: "#b0e0e6"},
{source: "12: health care services disposable medical", target: "12: medical capital equipment", fill: "#b0e0e6"},
{source: "12: Increasing ", target: "13: Facility Fee ", fill: "#ffc40c"},
{source: "13: Facility Fee ", target: "13: reimbursement", fill: "#ffc40c"},
{source: "13: reimbursement", target: "13: PVP in the United States ", fill: "#ffc40c"},
{source: "13: PVP in the United States ", target: "13: reduced further eliminated", fill: "#ffc40c"},
{source: "13: reduced further eliminated", target: "13: utilized by", fill: "#ffc40c"},
{source: "13: utilized by", target: "13: competitor", fill: "#ffc40c"},
{source: "13: Facility Fee ", target: "72: significant", fill: "#7b68ee"},
{source: "72: significant", target: "72: uncertainty", fill: "#7b68ee"},
{source: "72: uncertainty", target: "72: infringement", fill: "#7b68ee"},
{source: "72: significant", target: "104: new controls", fill: "#dcdcdc"},
{source: "104: new controls", target: "104: been implemented", fill: "#dcdcdc"},
{source: "104: been implemented", target: "104: future growth", fill: "#dcdcdc"},
{source: "104: future growth", target: "104: will depend on", fill: "#dcdcdc"},
{source: "104: will depend on", target: "104: improve operational", fill: "#dcdcdc"},
{source: "104: improve operational", target: "104: management", fill: "#dcdcdc"},
{source: "104: management", target: "104: control systems on", fill: "#dcdcdc"},
{source: "104: control systems on", target: "104: timely basis", fill: "#dcdcdc"},
{source: "104: timely basis", target: "104: together with", fill: "#dcdcdc"},
{source: "104: together with", target: "104: effective cost controls", fill: "#dcdcdc"},
{source: "104: new controls", target: "119: Accordingly ", fill: "#007ba7"},
{source: "119: Accordingly ", target: "119: risks actually materialize", fill: "#007ba7"},
{source: "119: risks actually materialize", target: "119: international", fill: "#007ba7"},
{source: "119: international", target: "119: operations may", fill: "#007ba7"},
{source: "119: operations may", target: "119: adversely affected", fill: "#007ba7"},
{source: "119: adversely affected", target: "119: international customers", fill: "#007ba7"},
{source: "119: international customers", target: "119: domestic customers", fill: "#007ba7"},
{source: "119: domestic customers", target: "119: use foreign fabrication plants may", fill: "#007ba7"},
{source: "119: use foreign fabrication plants may", target: "119: significant risks", fill: "#007ba7"},
{source: "119: significant risks", target: "119: product liability", fill: "#007ba7"},
{source: "119: product liability", target: "119: which could", fill: "#007ba7"},
{source: "119: which could", target: "119: insurance coverage", fill: "#007ba7"},
{source: "119: Accordingly ", target: "122: cannot predict", fill: "#c72"},
{source: "122: cannot predict", target: "122: adverse impact on", fill: "#c72"},
{source: "122: adverse impact on", target: "122: operations", fill: "#c72"},
{source: "122: operations", target: "122: future cash flows", fill: "#c72"},
{source: "122: cannot predict", target: "178: As of December ", fill: "#ffd800"},
{source: "178: As of December ", target: "178: total assets", fill: "#ffd800"},
{source: "178: total assets", target: "178: total liabilities", fill: "#ffd800"},
{source: "178: As of December ", target: "218: litigation", fill: "#4682b4"},
{source: "218: litigation", target: "218: court could", fill: "#4682b4"},
{source: "218: court could", target: "218: prohibit us from using technologies essential", fill: "#4682b4"},
{source: "218: prohibit us from using technologies essential", target: "218: products either", fill: "#4682b4"},
{source: "218: products either", target: "218: which would", fill: "#4682b4"},
{source: "218: which would", target: "218: operations", fill: "#4682b4"},
{source: "218: operations", target: "218: financial condition", fill: "#4682b4"},
{source: "218: litigation", target: "START_HERE", fill: "#4682b4"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Housewares and Specialties</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_mileage_reimbursement_rate">Business mileage reimbursement rate</a></td>
      <td>The business mileage reimbursement rate is an optional standard mileage rate used in the United States for purposes of computing the allowable business deduction, for Federal income tax purposes under the Internal Revenue Code, at 26 U.S.C. § 162, for the business use of a vehicle. Under the law, the taxpayer for each year is generally entitled to deduct either the actual expense amount, or an amount computed using the standard mileage rate, whichever is greater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reimbursement">Reimbursement</a></td>
      <td>Reimbursement is the act of compensating someone for an out-of-pocket expense by giving them an amount of money equal to what was spent.Companies, governments and nonprofit organizations may compensate their employees or officers for necessary and reasonable expenses; under US\nlaw, these expenses may be deducted from taxes by the organization and treated as untaxed income for the recipient provided that accountability conditions are met. UK law provides for deductions for travel and subsistence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ERISA_reimbursement">ERISA reimbursement</a></td>
      <td>In the United States, ERISA reimbursement refers to the efforts of an ERISA Plan administrator (an insurer) to obtain repayment from an insured person who had previously received payments for personal injury medical bills.When an insurer pays a injury claim to someone, the insurer can seize cash settlements from whoever caused the injury. This “right of reimbursement” is essentially a subrogation claim.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fee_Reimbursement_Scheme_(Andhra_Pradesh)">Fee Reimbursement Scheme (Andhra Pradesh)</a></td>
      <td>The Fee Reimbursement Scheme (also known as the Post-matric Scholarship Scheme) is a student education sponsorship programme of the Government of Andhra Pradesh. It supports students from lower economic strata in the state.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Laser_Clay_Shooting_System">Laser Clay Shooting System</a></td>
      <td>The Laser Clay Shooting System (レーザークレー射撃システム) is a light gun shooting simulation game created by Nintendo in 1973. The game consisted of an overhead projector which displayed moving targets behind a background; players would fire at the targets with a rifle, in which a mechanism of reflections would determine whether or not the "laser shot" from the rifle hit the target.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lidar">Lidar</a></td>
      <td>A lie is an assertion that is believed to be false, typically used with the purpose of deceiving someone. The practice of communicating lies is called lying.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Multiple_integrated_laser_engagement_system">Multiple integrated laser engagement system</a></td>
      <td>The multiple integrated laser engagement system, or MILES, is used by the U.S. military and other armed forces around the world for training purposes. It uses lasers and blank cartridges to simulate actual battle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_director">Operations director</a></td>
      <td>The role of operations director generally encompasses the oversight of operational aspects of company strategy with responsibilities to ensure operation information is supplied to the chief executive and the board of directors as well as external parties.\n\n\n== Description ==\nThe role of operations director can vary according to the size of a company, and at some companies many even encompass some or all the functions of a chief operating officer.The Institute of Directors of the United Kingdom defines the role as overseeing "all operational aspects of company strategy" and "responsible for the flow of operations information to the chief executive, the board and, where necessary, external parties such as investors or financial institutions".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>LASERSCOPE      Item 1A     Risk Factors             In determining whether to invest in our <font color="blue">common stock</font>, you should     <font color="blue">carefully</font>  consider  the  information  below  in addition to all other     information  provided to you in this Report, including the information     <font color="blue">incorporated by reference</font> in this Report</td>
    </tr>
    <tr>
      <td>The <font color="blue">statements under</font> this caption     are intended to <font color="blue">serve as cautionary statements within</font> the meaning of the     <font color="blue">Private Securities Litigation Reform Act </font>of 1995</td>
    </tr>
    <tr>
      <td>The following information     is not intended to limit in any way the <font color="blue">characterization</font> of other statements     or  information under other <font color="blue">captions as cautionary statements</font> for such     purpose</td>
    </tr>
    <tr>
      <td>Demand for our products <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and <font color="blue"><font color="blue">international</font>ly</font> is highly     <font color="blue">dependent</font> on the ability of physicians, hospitals and other <font color="blue">health care</font>     <font color="blue">facilities</font> to obtain satisfactory <font color="blue"><font color="blue">reimbursement</font> rates</font> for our products and     services  performed  with  our  <font color="blue">products from private</font> and <font color="blue"><font color="blue">government</font>al</font>     third-party  payers  as  well  as  direct  <font color="blue">payments from consumers</font></td>
    </tr>
    <tr>
      <td>If     satisfactory <font color="blue"><font color="blue">reimbursement</font> rates</font> are not maintained, demand for <font color="blue"><font color="blue">Laserscope </font>    </font><font color="blue">products would decline</font> and our business and financial results and <font color="blue">cash flows</font>     <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>A substantial portion of our <font color="blue">laser sales</font> are for <font color="blue">aesthetic procedures</font>     that <font color="blue">generally</font> are not covered or <font color="blue">reimbursed by <font color="blue">government</font></font> or commercial     health  insurance</td>
    </tr>
    <tr>
      <td>The <font color="blue">general absence</font> of <font color="blue">insurance coverage</font> for these     <font color="blue">cosmetic procedures may restrict</font> the <font color="blue">development</font> of this <font color="blue">market as growth</font> in     procedures  performed  with  our <font color="blue"><font color="blue">aesthetic products</font> largely depends on</font>     consumers’ willingness to pay out-of-pocket for these <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> of our products <font color="blue"><font color="blue">international</font>ly</font> may depend in part     upon the <font color="blue">availability</font> of <font color="blue"><font color="blue">reimbursement</font> within prevailing healthcare payment</font>     systems</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>and healthcare payment systems in <font color="blue">international</font>     markets vary <font color="blue"><font color="blue">significant</font>ly</font> by country and include both <font color="blue">government</font> sponsored     health  care  and  private  insurance</td>
    </tr>
    <tr>
      <td>We may not obtain <font color="blue">international</font>     <font color="blue">reimbursement</font>  approvals in a <font color="blue">timely manner</font>, if at all</td>
    </tr>
    <tr>
      <td>Our failure to     receive <font color="blue">international</font> <font color="blue">reimbursement</font> approvals may <font color="blue">negatively</font> impact market     <font color="blue">acceptance</font> of our products in the <font color="blue">international</font> markets in which those     approvals are sought</td>
    </tr>
    <tr>
      <td><font color="blue">Increasing </font>the use of our <font color="blue">GreenLight </font><font color="blue">laser system</font> to perform the     Photoselective Vaporization of the Prostate (“PVP”) <font color="blue">procedure could</font> be     <font color="blue">hindered by</font> the <font color="blue">ongoing efforts</font> of major third-party payers for <font color="blue">health care</font>     in  the  <font color="blue"><font color="blue">United States</font> </font>(such as Medicare, Medicaid, <font color="blue">private healthcare</font>     insurance and <font color="blue">managed care</font> plans) and in our key <font color="blue">international</font> markets such     as the European Union and the Asia-Pacific region to <font color="blue">contain healthcare</font>     costs  through stricter coverage criteria, price regulation, and lower     payments for all items, including <font color="blue">health care</font> services, disposable medical     products and <font color="blue">medical capital equipment</font></td>
    </tr>
    <tr>
      <td>The current <font color="blue">Facility Fee </font><font color="blue">reimbursement</font> for PVP <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>has been     reduced and could be reduced further, eliminated or <font color="blue">utilized by</font> a     <font color="blue">competitor</font></td>
    </tr>
    <tr>
      <td>Demand <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>for our <font color="blue">GreenLight </font><font color="blue">laser system</font> and     disposable  fiber  optic  delivery  devices is highly <font color="blue">dependent</font> on the     <font color="blue">reimbursement</font> for the PVP procedure when it is performed in the hospital     <font color="blue">outpatient setting</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">rate set by</font> Medicare is <font color="blue"><font color="blue">particularly</font> influential on</font>     demand because Medicare is the <font color="blue">largest single payer</font> for PVP procedures and     because many <font color="blue"><font color="blue">commercial payers</font> use</font> Medicare <font color="blue">payments as</font> a <font color="blue">benchmark</font> for     their <font color="blue"><font color="blue">reimbursement</font> rates</font></td>
    </tr>
    <tr>
      <td>The national <font color="blue">reimbursement</font> rate for the PVP     procedure was reduced to a new rate of <font color="blue">approximately</font> dlra2cmam500 for 2006</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>amount represents a decrease of dlra1cmam250 from the temporary <font color="blue">reimbursement</font>     amount of dlra3cmam750 per procedure <font color="blue">previously</font> in effect since April 2004, but is     <font color="blue">higher than</font> the dlra1cmam850 paid per procedure prior to April 2004</td>
    </tr>
    <tr>
      <td>Medicare pays for <font color="blue"><font color="blue">hospital outpatient</font> services on</font> a rate-per-service     basis  that  <font color="blue">varies according</font> to the <font color="blue">ambulatory payment</font> classification     (APC) group to which the service is assigned</td>
    </tr>
    <tr>
      <td>Services within a particular     APC are supposed to be like in clinical character and <font color="blue">resource utilization</font></td>
    </tr>
    <tr>
      <td>Medicare uses the <font color="blue">median cost</font> to establish a payment amount for the services     <font color="blue">grouped with</font> a single APC The <font color="blue"><font color="blue">hospital outpatient</font> payment rate</font> includes the     <font color="blue">national payment amount</font> that is made up of the Medicare payment and the     beneficiary co-payment to the <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Special payments are made under the     <font color="blue"><font color="blue">hospital outpatient</font> payment system</font> for <font color="blue">new <font color="blue">technology</font> items</font> in one of two     ways</td>
    </tr>
    <tr>
      <td>The first is through a temporary add-on payment or “<font color="blue">transitional</font>     pass-through  payments</td>
    </tr>
    <tr>
      <td>”  This  applies  to certain drugs, devices and     biologics</td>
    </tr>
    <tr>
      <td><font color="blue">The                                         </font>11       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>second  is through a <font color="blue">temporary assignment</font> to a <font color="blue"><font color="blue">New Technology </font>APC New     </font>services, not specific items, <font color="blue">generally</font> are <font color="blue">handled through</font> this method</td>
    </tr>
    <tr>
      <td><font color="blue">Assignment  </font>to  <font color="blue">a <font color="blue">New Technology </font>APC </font>is time limited</td>
    </tr>
    <tr>
      <td>Medicare has the     <font color="blue">discretion</font> to reassign a <font color="blue">New Technology </font>service to a standard clinical APC     when it feels it has <font color="blue">sufficient data</font> to understand the <font color="blue">costs incurred by</font>     hospitals to provide the service</td>
    </tr>
    <tr>
      <td>The APC <font color="blue">code applicable</font> to the PVP procedure has <font color="blue">varied since</font> its     launch</td>
    </tr>
    <tr>
      <td>We  submitted a <font color="blue">New Technology </font>Application to the Centers for     Medicare and Medicaid Services (“CMS”) in <font color="blue">September </font>2003, and was notified     by Medicare <font color="blue">several months afterwards</font> that the <font color="blue">application</font> was approved</td>
    </tr>
    <tr>
      <td>As     a result, PVP was assigned temporary HCPCS code C9713 and was assigned to     <font color="blue">New Technology </font>APC 1525, <font color="blue">effective</font> April 1, 2004</td>
    </tr>
    <tr>
      <td>The <font color="blue">national average</font>     payment  rate  for APC 1525 is dlra3cmam750</td>
    </tr>
    <tr>
      <td>In July 2005, CMS published its     <font color="blue">proposed rule</font> regarding the 2006 Outpatient Prospective Payment System     (“OPPS”) for outpatient hospital <font color="blue">facility</font> <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>In this rule, CMS     proposed  to  transfer  PVP  to a standard clinical Ambulatory Payment     Classification (“APC”) <font color="blue">code beginning</font> in 2006</td>
    </tr>
    <tr>
      <td>CMS <font color="blue">recently finalized</font> this     <font color="blue">proposal <font color="blue">based on</font></font> the agency’s belief that although it had less than a     full-year of hospital claims data for PVP, it had a sufficient number of     claims upon which to establish the <font color="blue">median cost</font> for performing the procedure     <font color="blue">billed under code</font> C9713, and, therefore, a <font color="blue">median cost</font> could be established</td>
    </tr>
    <tr>
      <td><font color="blue">As of January </font>1, 2006, PVP was assigned to APC 0429, which includes all     <font color="blue">prostate laser procedures described by</font> CPT codes 52647 and 52648</td>
    </tr>
    <tr>
      <td>The 2006     national <font color="blue">reimbursement</font> rate for APC 0429 is <font color="blue">approximately</font> dlra2cmam500</td>
    </tr>
    <tr>
      <td><font color="blue">Physician Fee Schedule </font><font color="blue">reimbursement</font> for PVP <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>remains     uncertain</td>
    </tr>
    <tr>
      <td><font color="blue">Demand in the US </font>for our <font color="blue">GreenLight </font><font color="blue">laser system</font> and disposable     <font color="blue"><font color="blue">fiber <font color="blue">optic delivery</font></font> devices</font> is also highly <font color="blue">dependent</font> on the <font color="blue">reimbursement</font>     rates  physicians  are paid to perform a PVP procedure</td>
    </tr>
    <tr>
      <td>In particular,     Medicare  payments to physicians for the PVP procedure are of critical     <font color="blue">importance as</font> Medicare is the <font color="blue">largest single payer</font> for PVP procedures and     its <font color="blue"><font color="blue">reimbursement</font> rates</font> are used as a <font color="blue">benchmark</font> by many <font color="blue">commercial payers</font></td>
    </tr>
    <tr>
      <td>Medicare pays for physician services under a uniform, national fee     <font color="blue">schedule <font color="blue">based on</font> <font color="blue">relative value units</font></font> (“RVUs”) that reflect the physician     work and <font color="blue"><font color="blue">overhead costs</font> <font color="blue">associated with</font> furnishing</font> a particular item or     service</td>
    </tr>
    <tr>
      <td>Medicare <font color="blue">assigns different</font> RVUs for a <font color="blue">single procedure depending on</font>     whether the service is performed in the physician’s office or a <font color="blue">facility</font>     such as a <font color="blue">hospital outpatient</font> department or <font color="blue">ambulatory surgery center</font></td>
    </tr>
    <tr>
      <td>The     non-<font color="blue">facility</font> payment rate is higher and is meant to reflect the fact that     <font color="blue">physicians incur greater <font color="blue">overhead costs</font></font> when they perform a procedure in     their office</td>
    </tr>
    <tr>
      <td><font color="blue">Prior to January </font>2006, physicians <font color="blue">generally</font> used CPT code 52647 to     describe to payers that they performed a PVP procedure</td>
    </tr>
    <tr>
      <td>A change in the CPT     <font color="blue">code descriptors</font> for CPT codes 52647 and 52648 became <font color="blue">effective</font> <font color="blue">January     </font>2006</td>
    </tr>
    <tr>
      <td>Under the new <font color="blue">descriptions</font>, PVP is more <font color="blue">appropriately described by</font>     52648</td>
    </tr>
    <tr>
      <td>Prior to the change, 52647 was <font color="blue">used most frequently</font> to describe PVP     Historically, CPT code 52648 was not assigned non-<font color="blue">facility</font> practice expense     <font color="blue">relative value units</font> (RVUs)</td>
    </tr>
    <tr>
      <td>Consequently, despite the fact that physicians     have been performing PVP in a well-equipped office setting, there would no     longer have been a mechanism to <font color="blue">reimburse physicians</font> for the <font color="blue">overhead costs</font>     of performing PVP in the non-<font color="blue">facility</font> setting</td>
    </tr>
    <tr>
      <td>CMS published a technical     revision  to  the 2006 Medicare <font color="blue">physician fee schedule</font> to address this     situation</td>
    </tr>
    <tr>
      <td>Thus, the total     national 2006 <font color="blue">reimbursement</font> rate <font color="blue">for a PVP </font>procedure performed in the office     is <font color="blue">approximately</font> dlra3cmam100</td>
    </tr>
    <tr>
      <td>There  is the chance that at some time in the future PVP may be     assigned a <font color="blue">payment level</font> that does not <font color="blue">pay physicians at</font> a rate they feel     <font color="blue">adequately reflects</font> the time, effort and <font color="blue">resource costs <font color="blue">associated with</font></font> the     procedure</td>
    </tr>
    <tr>
      <td>Similarly, should Medicare underpay PVP     relative to other procedures it <font color="blue">will <font color="blue">negatively</font> influence physician adoption</font>     of the PVP procedure, <font color="blue"><font color="blue">which would</font> reduce demand</font> for our products and harm     our  financial  performance</td>
    </tr>
    <tr>
      <td>CMS <font color="blue">reimbursement</font> decisions regarding the     physician <font color="blue">Fee Schedule for PVP </font>in any site of <font color="blue">service remain uncertain</font> and     could result in maintenance of the current <font color="blue">reimbursement</font> structure or a     decrease in <font color="blue"><font color="blue">reimbursement</font> rates</font> <font color="blue">which could</font> <font color="blue">adversely</font> affect PVP procedural     volume and sales of our products</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>PVP physician <font color="blue">reimbursement</font> is typically lower, on a per-procedure basis,     compared to other BPH therapies</td>
    </tr>
    <tr>
      <td>The current <font color="blue">national average</font> rate of <font color="blue">reimbursement</font> paid by Medicare to     physicians for performing the PVP <font color="blue">procedure on</font> a per-procedure basis is, in     some  cases,  <font color="blue"><font color="blue">substantially</font> lower than</font> the <font color="blue">reimbursement</font> rate paid for     performing certain other <font color="blue">minimally invasive</font> BPH <font color="blue">therapies on</font> a per-procedure     basis</td>
    </tr>
    <tr>
      <td>While we believe that this <font color="blue">disparity</font> results in physicians and     hospitals not being <font color="blue">reimbursed at</font> a <font color="blue">rate <font color="blue">commensurate</font> with</font> the <font color="blue">necessary</font>     resources and work required to do the PVP procedure in all sites of service     currently being used by physicians, there can be no assurance that CMS will     adjust <font color="blue"><font color="blue">reimbursement</font> rates</font> to address this <font color="blue">disparity</font></td>
    </tr>
    <tr>
      <td>Further, there can be     no assurance that physician <font color="blue">reimbursement</font> for these other therapies will not     be maintained at current levels or <font color="blue">raised relative</font> to <font color="blue">reimbursement</font> for PVP     or that the physician <font color="blue">reimbursement</font> for PVP will be maintained at current     levels or <font color="blue">increased relative</font> to other BPH therapies</td>
    </tr>
    <tr>
      <td>The <font color="blue">adoption rate</font> of     the PVP procedure <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>is highly <font color="blue">dependent</font> upon hospital and     <font color="blue">physician economics</font></td>
    </tr>
    <tr>
      <td>A substantial reduction in payments to <font color="blue">facilities</font>     and/or a <font color="blue">continuation</font> of the <font color="blue">disparity</font> which currently exists between the     physician <font color="blue">reimbursement</font> for certain other BPH therapies and that for PVP     could cause a reduction in the adoption of PVP <font color="blue">by hospitals</font> and physicians,     <font color="blue"><font color="blue">which would</font> reduce demand</font> for our products and harm our business</td>
    </tr>
    <tr>
      <td>If we are not able to protect our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> adequately</font>, we will     lose a critical competitive advantage, which will reduce our revenues,     profits and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>Our  patents,  <font color="blue">copyrights</font>,  trademarks, trade secrets and other     <font color="blue"><font color="blue">intellectual</font> property</font> are critical to our success</td>
    </tr>
    <tr>
      <td>We hold <font color="blue">several patents</font>     issued in the <font color="blue">United States</font>, <font color="blue">generally</font> covering surgical <font color="blue">laser system</font>s,     <font color="blue">delivery devices</font>, calibration inserts and the <font color="blue">laser resonator</font></td>
    </tr>
    <tr>
      <td>We have also     <font color="blue">licensed certain <font color="blue">technologies</font> from others</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that any patents or licenses that we hold or that may     be  issued  as  a  result  of our patent <font color="blue">application</font>s will provide any     <font color="blue">competitive advantages</font> for our products</td>
    </tr>
    <tr>
      <td>Nor can we assure that any of the     patents that we now hold or may hold in the future will not be <font color="blue">successfully</font>     challenged, invalidated or <font color="blue">circumvented</font> in the future</td>
    </tr>
    <tr>
      <td>In addition, we     <font color="blue">cannot assure</font> that <font color="blue">competitor</font>s, many of which have substantial resources and     have made substantial <font color="blue">investments</font> in competing <font color="blue">technologies</font>, will not seek     to apply for and obtain patents that will prevent, limit or <font color="blue">interfere with</font>     our ability to make, issue, use and sell our products</td>
    </tr>
    <tr>
      <td>Furthermore, we cannot be certain that the steps we have <font color="blue">taken will</font>     prevent the <font color="blue">misappropriation</font> of our <font color="blue"><font color="blue">intellectual</font> property</font>, <font color="blue">particularly</font> in     <font color="blue">foreign countries</font> where the laws may not protect our <font color="blue">proprietary rights as</font>     fully  as in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We have not attempted to <font color="blue">secure patent</font>     protection in <font color="blue">foreign countries</font>, and the laws of some <font color="blue">foreign countries</font> may     not <font color="blue">adequately protect</font> our <font color="blue"><font color="blue">intellectual</font> property</font> as well as the laws of the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>As we increase our <font color="blue">international</font> presence, we expect that it     will  become  more  <font color="blue">difficult</font>  to monitor the <font color="blue">development</font> of competing     <font color="blue">technologies</font> that <font color="blue">may infringe on</font> our <font color="blue">rights as well as unauthorized use</font> of     our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We believe that we own or have the right to use the <font color="blue">basic patents</font>     covering our products</td>
    </tr>
    <tr>
      <td>However, the laser industry is <font color="blue">characterized</font> by a     very large number of patents, some of which appear to overlap with other     issued patents</td>
    </tr>
    <tr>
      <td>As a result, there is a <font color="blue">significant</font> amount of <font color="blue">uncertainty</font> in     the industry regarding patent protection and <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Because patent     <font color="blue">application</font>s are maintained in secrecy <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>until such     patents  are issued and are maintained in secrecy for a period of time     outside the <font color="blue">United States</font>, we can <font color="blue">conduct only</font> limited searches to determine     whether our <font color="blue"><font color="blue">technology</font> infringes</font> any patents or patent <font color="blue">application</font>s of     others</td>
    </tr>
    <tr>
      <td>If we are unable to protect the integrity, safety and proper use of our     disposable  <font color="blue">fiber <font color="blue">optic delivery</font></font> device used with the <font color="blue">GreenLight </font>laser     system,  it  could  result in <font color="blue">negative patient outcomes</font> and reduce our     <font color="blue">disposable delivery</font> device <font color="blue">recurring <font color="blue">revenue stream</font></font></td>
    </tr>
    <tr>
      <td>Ensuring the integrity, safety and proper use of the <font color="blue">GreenLight </font>PV     <font color="blue">disposable fiber optical delivery</font> device, <font color="blue">also known as</font> the ADDStat fiber     <font color="blue">optic delivery</font> device, and referred to elsewhere in this Report as the     “delivery device”, used with the <font color="blue">GreenLight </font>PV <font color="blue">laser system</font> is crucial to     achieving <font color="blue">optimal patient outcomes from</font> the PVP procedure</td>
    </tr>
    <tr>
      <td>With this is     mind, we <font color="blue">manufacture</font> the <font color="blue">GreenLight </font>PV delivery device                                         13       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font><font color="blue">using high quality materials</font> and <font color="blue">exacting production standards</font></td>
    </tr>
    <tr>
      <td>We inspect     each unit <font color="blue">carefully</font> to check that it conforms to our <font color="blue">specifications</font> and use     <font color="blue">diligent efforts</font> to ensure that the delivery device is <font color="blue">used appropriately</font> in     <font color="blue">connection with</font> the <font color="blue">GreenLight </font>PV <font color="blue">laser system</font></td>
    </tr>
    <tr>
      <td>However, if a <font color="blue">third party</font>     were to produce and distribute a <font color="blue"><font color="blue">counterfeit</font> version</font> of the <font color="blue">GreenLight </font>PV     delivery device or an inferior <font color="blue">substitute delivery</font> device to our customers,     use of inferior materials, poor design, shoddy construction or improper     handling or use of <font color="blue">such products could</font> result in <font color="blue">severe adverse patient</font>     events</td>
    </tr>
    <tr>
      <td>While we are <font color="blue">constantly</font> making <font color="blue">diligent efforts</font> to promote positive     <font color="blue">clinical outcomes by protecting</font> the safety, integrity and proper use of our     products, <font color="blue">particularly</font> the <font color="blue">GreenLight </font>PV delivery device, one or more third     party <font color="blue">manufacture</font>rs may produce <font color="blue">counterfeit</font> or inferior <font color="blue">quality delivery</font>     devices that our customers may, knowingly or unknowingly, purchase for use     with the <font color="blue">GreenLight </font>PV <font color="blue">laser system</font></td>
    </tr>
    <tr>
      <td>In addition, it is possible that our     <font color="blue">customers may seek</font> to violate our <font color="blue">prohibition on reuse</font> of <font color="blue">delivery devices</font>     (or reuse inferior <font color="blue">substitute delivery</font> devices) on unwitting patients,     reducing the efficacy of the procedure and <font color="blue">exposing such patients</font> to the     risk of blood-borne pathogens</td>
    </tr>
    <tr>
      <td>Use of such <font color="blue">third party</font> <font color="blue">delivery devices</font> or     misuse of our genuine <font color="blue">GreenLight </font>PV <font color="blue">delivery devices</font> could result in adverse     clinical outcomes, <font color="blue">potentially</font> reducing demand for PVP and <font color="blue">decreasing</font> demand     for our products</td>
    </tr>
    <tr>
      <td>Although we use a variety of methods to <font color="blue">protect patients</font>     from inferior <font color="blue">delivery devices</font> and the reuse of our <font color="blue">GreenLight </font>PV delivery     devices, including legal and <font color="blue">regulatory</font> safeguards, system enabling, patient     <font color="blue">education</font>  and  <font color="blue">safety packaging among</font> other measures, there can be no     assurance that such methods will be <font color="blue"><font color="blue">effective</font> at avoiding</font> the <font color="blue">introduction</font>     of  such  <font color="blue">counterfeit</font>  or <font color="blue">substitute delivery</font> devices into the market</td>
    </tr>
    <tr>
      <td>Moreover, use of <font color="blue">counterfeit</font> or substitute <font color="blue">disposable delivery</font> devices for     use with the <font color="blue">GreenLight </font>PV <font color="blue">laser system</font> or <font color="blue">unauthorized reuse</font> of delivery     devices, would displace sales of our <font color="blue">GreenLight </font>PV <font color="blue">disposable delivery</font>     <font color="blue">devices reducing</font> our recurring <font color="blue">disposable delivery</font> device <font color="blue">revenue stream</font> and     harming our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">participate</font> in <font color="blue">competitive markets with companies</font> that have <font color="blue"><font color="blue">significant</font>ly</font>     greater financial, technical, research and <font color="blue">development</font>, <font color="blue">manufacturing</font> and     marketing  resources  and/or  who produce standard, <font color="blue">entrenched medical</font>     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We compete in the non-ophthalmic surgical segment of the worldwide     <font color="blue">medical laser market</font></td>
    </tr>
    <tr>
      <td>In this market, lasers are used in hospital operating     rooms, outpatient surgery centers and individual <font color="blue">physician offices</font> for a     wide  variety  of  procedures</td>
    </tr>
    <tr>
      <td>This market is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitor</font>s  are  numerous  and  include  some  of the world’s largest     organizations as well as smaller, highly specialized firms</td>
    </tr>
    <tr>
      <td>Our ability to     <font color="blue"><font color="blue">compete <font color="blue">effective</font>ly</font> depends on such factors as</font>:         •  market <font color="blue">acceptance</font> of our products;         •  <font color="blue">product performance</font>;         •  price;         •  satisfactory <font color="blue">reimbursement</font> of the PVP <font color="blue">procedure by public</font> and private     <font color="blue">third party</font> payers;         •  <font color="blue">customer support</font>;         •  the success and timing of new product <font color="blue">development</font>; and         •  continued <font color="blue">development</font> of <font color="blue">successful <font color="blue">distribution</font> channels</font></td>
    </tr>
    <tr>
      <td>Some of our current and prospective <font color="blue">competitor</font>s have or may have     <font color="blue"><font color="blue">significant</font>ly</font>  greater financial, technical, research and <font color="blue">development</font>,     <font color="blue">manufacturing</font> and marketing resources than we have</td>
    </tr>
    <tr>
      <td>To <font color="blue">compete <font color="blue">effective</font>ly</font>,     we will need to continue to expand our product offerings, periodically     enhance our <font color="blue">existing products</font> and continue to enhance our <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>Certain <font color="blue">surgical laser</font> <font color="blue">manufacture</font>rs have targeted their <font color="blue">efforts on</font>     narrow  segments  of the market, such as angioplasty, orthopedics, and     <font color="blue">lithotripsy</font></td>
    </tr>
    <tr>
      <td>Their products may compete for the <font color="blue">same capital equipment</font> and     disposable  device  funds  as  our  products,  and  <font color="blue">accordingly</font>, these     <font color="blue">manufacture</font>rs may be considered our <font color="blue">competitor</font>s</td>
    </tr>
    <tr>
      <td>Generally, <font color="blue">surgical laser</font>     <font color="blue">manufacture</font>rs such as us compete with standard                                         14       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font><font color="blue">surgical methods</font> and other medical <font color="blue">technologies</font> and <font color="blue">treatment modalities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Several  </font>of  these <font color="blue">manufacture</font>rs and their <font color="blue">distribution</font> partners offer     products for the treatment of BPH using similar <font color="blue">technologies</font> to ours and     engage in <font color="blue">aggressive</font> marketing campaigns, pricing, and <font color="blue">promotional efforts</font>     <font color="blue">targeted at</font> our products and customers</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that we can compete     <font color="blue">effective</font>ly against such <font color="blue">competitor</font>s</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">cannot assure</font> that     these  or other <font color="blue">companies will</font> not succeed in developing <font color="blue">technologies</font>,     products or <font color="blue">treatments</font> that are more <font color="blue"><font color="blue">effective</font> than ours</font> or that would     render our <font color="blue">technology</font> or <font color="blue">products obsolete</font> or non-competitive</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">effective</font>ly manage</font> our growth, our business may be     harmed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success depends on</font> our ability to <font color="blue">successfully</font> manage our     growth</td>
    </tr>
    <tr>
      <td>Our  ability to manage our business <font color="blue">successfully</font> in a rapidly     evolving and <font color="blue">extremely competitive market</font> requires an <font color="blue">effective</font> planning and     <font color="blue"><font color="blue">management</font> process</font></td>
    </tr>
    <tr>
      <td>Our rates of growth in <font color="blue">recent years</font> have been high</td>
    </tr>
    <tr>
      <td>Should our business continue to grow and demand for our <font color="blue">products continue</font> to     <font color="blue">increase at</font> similar rates, it <font color="blue">will increase</font> the strain on our personnel in     all aspects of our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">historical growth</font> and <font color="blue">international</font> expansion, have placed, and     are expected to continue to place, a <font color="blue">significant</font> strain on our managerial,     operational and <font color="blue">financial resources</font> as well as our financial and <font color="blue">management</font>     controls, reporting systems and procedures</td>
    </tr>
    <tr>
      <td>Although some <font color="blue">new controls</font>,     systems and procedures have <font color="blue">been implemented</font>, our <font color="blue">future growth</font>, if any,     <font color="blue">will depend on</font> our ability to continue to implement and <font color="blue">improve operational</font>,     financial and <font color="blue">management</font> information and <font color="blue">control systems on</font> a <font color="blue">timely basis</font>,     <font color="blue">together with</font> maintaining <font color="blue">effective</font> cost controls</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to manage     any  future  growth  <font color="blue">effective</font>ly  would be harmful to our revenues and     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our dependence on certain single-source suppliers and certain other third     <font color="blue">parties could <font color="blue">adversely</font> impact</font> our ability to <font color="blue">manufacture</font> lasers</td>
    </tr>
    <tr>
      <td>Certain of the <font color="blue"><font color="blue">components</font> used</font> in our <font color="blue">laser products</font>, including     <font color="blue">certain optical <font color="blue">components</font></font>, are <font color="blue">purchased from single sources</font></td>
    </tr>
    <tr>
      <td>While we     believe that most of these <font color="blue">components</font> are <font color="blue">available from alternate sources</font>,     an  <font color="blue">interruption</font> of these or other <font color="blue">supplies could <font color="blue">adversely</font> affect</font> our     ability to <font color="blue">manufacture</font> lasers</td>
    </tr>
    <tr>
      <td>Problems <font color="blue">associated with</font> <font color="blue">international</font> business <font color="blue"><font color="blue">operations</font> could affect</font> our     ability to sell our products</td>
    </tr>
    <tr>
      <td>As our <font color="blue">international</font> business has grown, we have <font color="blue">become increasingly</font>     subject to the risks arising from the unique and <font color="blue"><font color="blue">potentially</font> adverse factors</font>     in the countries in which we operate</td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> revenues were 31prca of     <font color="blue">total revenues</font> in the year ended <font color="blue">December </font>31, 2005 and 27prca in the year ended     <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> sales are made through <font color="blue">international</font>     <font color="blue">distributors</font> and wholly-owned subsidiaries with payments to us typically     <font color="blue">denominated</font> in the <font color="blue">local currencies</font> of the United Kingdom and France, and in     <font color="blue"><font color="blue">United States</font> </font>Dollars in the rest of the world</td>
    </tr>
    <tr>
      <td>We intend to continue our     <font color="blue"><font color="blue">operations</font> outside</font> of the <font color="blue"><font color="blue">United States</font> </font>and <font color="blue">potentially</font> to enter <font color="blue">additional</font>     <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>We anticipate that sales to <font color="blue">customers located outside</font>     <font color="blue">North America </font><font color="blue">will increase</font> and <font color="blue">will continue</font> to represent a <font color="blue">significant</font>     portion of our <font color="blue">total revenues</font> in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">activities</font>, require     <font color="blue">significant</font> <font color="blue">management</font> attention and <font color="blue">financial resources</font> and further subject     us to the risks of operating <font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>These risks include, but are     not limited to:         •  changes in <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>;         •  delays resulting from <font color="blue">difficult</font>y in obtaining <font color="blue">export licenses</font> for     certain <font color="blue">technology</font>;         •  customs, tariffs and other barriers and <font color="blue">restrictions</font>; and         •  the burdens of <font color="blue">complying with</font> a variety of <font color="blue">foreign laws</font></td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font>      We are also subject to <font color="blue">general geopolitical risks</font> in <font color="blue">connection with</font>     our <font color="blue">international</font> <font color="blue">operations</font>, such as:         •  <font color="blue">differing economic conditions</font>;         •  changes in <font color="blue">political climate</font>;         •  <font color="blue">differing tax structures</font>; and         •  changes in diplomatic and <font color="blue">trade <font color="blue">relationship</font>s</font> and war</td>
    </tr>
    <tr>
      <td>In addition, fluctuations in <font color="blue">currency exchange rates may <font color="blue">negatively</font></font>     affect our ability to compete in terms of price against products <font color="blue">denominated</font>     in <font color="blue">local currencies</font></td>
    </tr>
    <tr>
      <td>Accordingly, if these <font color="blue">risks actually materialize</font>, our <font color="blue">international</font>     <font color="blue"><font color="blue">operations</font> may</font> be <font color="blue"><font color="blue">adversely</font> affected</font> and sales to <font color="blue">international</font> customers,     as well as those <font color="blue">domestic customers</font> that use foreign fabrication plants, may     decrease       Our business has <font color="blue">significant</font> risks of <font color="blue">product liability</font> claims, <font color="blue">which could</font>     drain our resources and exceed our limited <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>Our business has <font color="blue">significant</font> risks of <font color="blue">product liability</font> claims</td>
    </tr>
    <tr>
      <td>We     have  experienced <font color="blue">product liability</font> claims from time to time, which we     believe are ordinary for our business</td>
    </tr>
    <tr>
      <td>While we <font color="blue">cannot predict</font> or determine     the outcome of the actions <font color="blue">brought against us</font>, we believe that these actions     will  not  ultimately  have a material <font color="blue">adverse <font color="blue">impact on</font></font> our financial     position, results of <font color="blue">operations</font>, and future <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>At present, we maintain <font color="blue">product liability</font> insurance on a “claims     made” <font color="blue">basis with coverage <font color="blue">commensurate</font> with</font> our business and <font color="blue"><font color="blue">product line</font>s</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that such <font color="blue">insurance coverage</font> will be available to us in the     future at a <font color="blue">reasonable cost</font>, if at all, nor can we assure that other claims     will not be <font color="blue">brought against us</font> in excess of our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>Our products are subject to <font color="blue">government</font> regulation, and we <font color="blue">cannot assure</font> that     all <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals, including approvals for <font color="blue">new products</font> or     product improvements, will be <font color="blue">granted on</font> a <font color="blue">timely basis</font>, if at all, and that     we won’t be subject to <font color="blue">product recalls</font> or warnings and other <font color="blue">regulatory</font>     actions and penalties that <font color="blue">could <font color="blue">materially</font> affect</font> our operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>regulation <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and other countries is a     <font color="blue">significant</font> factor in the <font color="blue">development</font>, <font color="blue">manufacturing</font> and marketing of many     of our products</td>
    </tr>
    <tr>
      <td>Our products are regulated <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>by the Food and Drug     Administration under the Federal Food, Drug and Cosmetic Act (the “FDC     Act”) and the Radiation Control for Health and Safety Act</td>
    </tr>
    <tr>
      <td><font color="blue">The FDC Act     </font><font color="blue">provides two basic review procedures</font> for <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>Certain products     qualify  for  a  Section 510(k)  (“510(k)”)  <font color="blue">procedure under which</font> the     <font color="blue">manufacture</font>r gives the FDA pre-market notification of the <font color="blue">manufacture</font>r’s     intention to <font color="blue">commence marketing</font> the product</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font>r must, among     other things, establish that the product to be marketed is “<font color="blue">substantially</font>     equivalent”  to  a  <font color="blue">previously</font>  marketed  product</td>
    </tr>
    <tr>
      <td>In some cases, the     <font color="blue">manufacture</font>r may be required to include <font color="blue">clinical data</font> gathered under an     <font color="blue">investigational</font> device exemption (“IDE”) <font color="blue">granted by</font> the FDA <font color="blue">allowing human</font>     <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that the FDA <font color="blue">will grant marketing clearance</font>     for our <font color="blue">future products on</font> a <font color="blue">timely basis</font>, or at all</td>
    </tr>
    <tr>
      <td>If  the  product does not qualify for the 510(k) procedure, the     <font color="blue">manufacture</font>r must file a pre-market approval <font color="blue">application</font> (“PMA”) <font color="blue">based on</font>     <font color="blue">testing intended</font> to <font color="blue">demonstrate</font> that the product is both safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>The PMA requires more extensive <font color="blue">clinical testing than</font> the 510(k) procedure     and <font color="blue">generally</font> involves a <font color="blue"><font color="blue">significant</font>ly</font> longer FDA <font color="blue">review process</font></td>
    </tr>
    <tr>
      <td><font color="blue">Approval     </font>of  a  PMA <font color="blue">allowing commercial sale</font> of a product requires pre-clinical     <font color="blue">laboratory</font> and <font color="blue">animal tests</font> and human <font color="blue">clinical studies</font> conducted under an     IDE <font color="blue">establishing safety</font> and <font color="blue">effective</font>ness</td>
    </tr>
    <tr>
      <td>Generally, because of the amount     of information required, the 510(k) procedure takes less time than the PMA     procedure</td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font>       In  addition, we are subject to review, periodic inspection and     marketing  surveillance  by  the  FDA to determine our <font color="blue">compliance with</font>     <font color="blue">regulatory</font>  <font color="blue">requirements</font> for any product for which we obtain marketing     approval</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>approval, our <font color="blue">manufacturing</font> processes, subsequent     <font color="blue">clinical data</font> and promotional <font color="blue">activities</font> are subject to ongoing <font color="blue">regulatory</font>     <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>finds that we have failed to comply with these     <font color="blue">requirements</font>  or  later discovers <font color="blue">previously</font> unknown problems with our     products, including <font color="blue">unanticipated adverse events</font> of <font color="blue">unanticipated severity</font>     or frequency, <font color="blue">manufacture</font> or <font color="blue">manufacturing</font> processes or failure to comply     with <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>, it can institute a wide variety of <font color="blue">enforcement</font>     actions, ranging from a <font color="blue">public warning letter</font> to more <font color="blue">severe sanctions</font>,     including:         •  fines, <font color="blue">injunctions</font> and <font color="blue">civil penalties</font>;         •  recall or seizure of our products;         •  <font color="blue">restrictions</font> on our products or <font color="blue">manufacturing</font> processes, including     operating <font color="blue">restrictions</font>, partial suspension or <font color="blue">total shutdown</font> of production;         •  denial of requests for 510(k) <font color="blue">clearances</font> or PMAs of product <font color="blue">candidates</font>;         •  withdrawal of 510(k) <font color="blue">clearances</font> or PMAs <font color="blue">already granted</font>;         •  <font color="blue">disgorgement</font> of profits; and         •  <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Any  of  these  <font color="blue">enforcement</font> actions could affect our ability to     <font color="blue">commercially</font> distribute our products <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and may also harm     our  ability  to  conduct the clinical trials <font color="blue">necessary</font> to support the     marketing, clearance or approval of these products and could <font color="blue">materially</font> and     <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>To date, all of our products (except for the 800 and 600 Series Dye     Module) have <font color="blue">been marketed through</font> the 510(k) procedure</td>
    </tr>
    <tr>
      <td>Future products,     however, may require <font color="blue">clearance through</font> the PMA procedure</td>
    </tr>
    <tr>
      <td>There can be no     assurance that such marketing <font color="blue">clearances</font> can be obtained on a <font color="blue">timely basis</font>,     or at all</td>
    </tr>
    <tr>
      <td>Delays in receiving such <font color="blue">clearances</font> could have a <font color="blue">significant</font>     <font color="blue">adverse <font color="blue">impact on</font></font> our ability to compete in our industry</td>
    </tr>
    <tr>
      <td>The FDA may also     require post-market testing and <font color="blue">surveillance programs</font> to <font color="blue">monitor certain</font>     products</td>
    </tr>
    <tr>
      <td>Certain other countries require medical device <font color="blue">manufacture</font>rs to obtain     <font color="blue">clearances</font> for products prior to marketing the products in those countries</td>
    </tr>
    <tr>
      <td>The <font color="blue">requirements</font> vary widely from country to country and are subject to     change</td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining </font><font color="blue">necessary</font> <font color="blue">regulatory</font> approvals in key <font color="blue">international</font>     markets and retaining such <font color="blue">regulatory</font> licenses is essential to <font color="blue">international</font>     expansion of our business, which is an <font color="blue">important strategic objective</font></td>
    </tr>
    <tr>
      <td>We are also required to <font color="blue">register with</font> the FDA and state agencies, such     as the Food and Drug Branch of the California Department of Health Services     (“CDHS”), as a medical device <font color="blue">manufacture</font>r</td>
    </tr>
    <tr>
      <td>We are inspected <font color="blue">routinely by</font>     these agencies to determine our <font color="blue">compliance with</font> the FDA’s current “Quality     Systems  Regulations”</td>
    </tr>
    <tr>
      <td>Those <font color="blue"><font color="blue">regulations</font> impose certain procedural</font> and     documentation <font color="blue">requirements</font> upon medical device <font color="blue">manufacture</font>rs concerning     <font color="blue">manufacturing</font>, testing and quality control <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">inspections</font>     determine violations of <font color="blue">applicable <font color="blue">regulations</font></font>, the <font color="blue">continued marketing</font> of     any products <font color="blue">manufacture</font>d by us may be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">laser products</font> are <font color="blue">covered by</font> a performance standard     for <font color="blue">laser products</font> set forth in FDA <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">laser performance</font>     standard  imposes  certain specific record-keeping, reporting, product     testing, and product labeling <font color="blue">requirements</font> on laser <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">requirements</font> also include <font color="blue">affixing warning labels</font> to <font color="blue">laser system</font>s, as well     <font color="blue">as incorporating certain safety</font> features in the design of <font color="blue">laser products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Complying </font>with applicable <font color="blue"><font color="blue">government</font>al</font> <font color="blue">regulations</font> and obtaining     <font color="blue">necessary</font> <font color="blue">clearances</font> or approvals can be time consuming and expensive</td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>can be no assurance that <font color="blue">regulatory</font> review will not involve delays or other     actions <font color="blue">adversely</font> affecting the marketing and sale of our products in the     <font color="blue"><font color="blue">United States</font> </font>and                                         17       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>We also <font color="blue">cannot predict</font> the extent or impact of future     <font color="blue">legislation</font> or <font color="blue">regulations</font> <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and abroad</td>
    </tr>
    <tr>
      <td>We  are also subject to <font color="blue">regulation under federal</font> and state laws     regarding, among other things, occupational safety, the use and handling of     <font color="blue">hazardous materials</font> and protection of the <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>While we believe that     we are in material <font color="blue">compliance with</font> these <font color="blue">requirements</font>, non<font color="blue">compliance with</font>     any such <font color="blue">requirements</font> could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> approval process outside the <font color="blue"><font color="blue">United States</font> </font><font color="blue">varies depending</font>     on foreign <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> and may limit our ability to develop,     <font color="blue">manufacture</font> and sell our products <font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>To market any of our <font color="blue">products outside</font> of the <font color="blue">United States</font>, we and our     <font color="blue">collaborative partners</font>, including certain of our <font color="blue">distributors</font>, are subject     to numerous and varying foreign <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>, implemented by     foreign  <font color="blue">health authorities</font>, governing the design and conduct of human     clinical  trials and <font color="blue">marketing approval</font> for <font color="blue">diagnostic products</font></td>
    </tr>
    <tr>
      <td>As an     example, we are seeking <font color="blue">regulatory</font> approval to market the <font color="blue">GreenLight </font>laser     system for the treatment of BPH in Japan, which we hope will be received     before  the  end of 2007</td>
    </tr>
    <tr>
      <td>The approval     <font color="blue">procedure varies among countries</font> and can involve <font color="blue">additional</font> testing, and the     time required to obtain <font color="blue">approval may differ from</font> that required to obtain FDA     approval</td>
    </tr>
    <tr>
      <td>The foreign <font color="blue">regulatory</font> approval process includes all of the risks     <font color="blue">associated with</font> obtaining FDA <font color="blue">approval set forth</font> above, and <font color="blue">approval by</font> the     FDA does not ensure <font color="blue">approval by</font> the <font color="blue">health authorities</font> of any other country,     nor does the <font color="blue">approval by</font> foreign <font color="blue">health authorities</font> ensure <font color="blue">approval by</font> the     FDA       If  our  dispute  with Palomar is resolved in a <font color="blue">manner contrary</font> to our     position, we could be required to record <font color="blue">additional</font> expenses <font color="blue">which could</font>     have a material <font color="blue">adverse <font color="blue">impact on</font></font> our financial results</td>
    </tr>
    <tr>
      <td>Palomar Medical Technologies, Inc</td>
    </tr>
    <tr>
      <td>(“Palomar”) has <font color="blue">informed us</font> that it     disputes the <font color="blue">method used by us</font> for <font color="blue">calculating</font> the royalty to be paid on the     Lyra  laser  system  pursuant  to the <font color="blue">Patent <font color="blue">License Agreement</font> </font>between     <font color="blue">Laserscope </font>and Palomar (the “<font color="blue">License Agreement</font>”)</td>
    </tr>
    <tr>
      <td>Palomar <font color="blue">also disputes</font> our     <font color="blue">application</font> of the <font color="blue">License Agreement</font> to the Gemini <font color="blue">laser system</font>, including     our  <font color="blue">calculation</font> of <font color="blue">royalties due on</font> the Gemini <font color="blue">laser system</font> under the     <font color="blue">License Agreement</font></td>
    </tr>
    <tr>
      <td>In the third quarter of 2005, Palomar exercised its right     under the <font color="blue">License Agreement</font> to engage an in<font color="blue">dependent</font> auditor to conduct a     review of our royalty <font color="blue">calculation</font>s and payments under the <font color="blue">License Agreement</font></td>
    </tr>
    <tr>
      <td>The in<font color="blue">dependent</font> auditors have issued a report identifying <font color="blue">several potential</font>     <font color="blue">alternative interpretations</font> of the <font color="blue">application</font> of the <font color="blue">License Agreement</font> that     indicate a <font color="blue">potential liability</font> of up to dlra3dtta7 million</td>
    </tr>
    <tr>
      <td>We <font color="blue">disagree with each</font>     of these potential <font color="blue">alternative interpretations</font> and believe that we have been     correctly <font color="blue">calculating</font> and paying the <font color="blue">royalties owed</font> to Palomar under the     <font color="blue">License Agreement</font></td>
    </tr>
    <tr>
      <td>Although we intend to <font color="blue">vigorously defend</font> our position     while we seek to negotiate a resolution of the <font color="blue">dispute with</font> Palomar, we may     be  unable  to  reach  a mutually agreeable resolution of the dispute</td>
    </tr>
    <tr>
      <td>Additionally, we have not accrued for a settlement of the dispute</td>
    </tr>
    <tr>
      <td>If our     <font color="blue">dispute with</font> Palomar is resolved in a <font color="blue">manner contrary</font> to our position, we     could be required to litigate the dispute incurring <font color="blue">significant</font> expenses and     risk an <font color="blue">unfavorable judgment</font>, to record <font color="blue">additional</font> expenses and/or to pay a     material amount to settle the dispute, <font color="blue">which could</font> have a material adverse     <font color="blue">impact on</font> our financial results</td>
    </tr>
    <tr>
      <td>As we have limited working capital, we may need <font color="blue">additional</font> capital that may     not  be  available  to us and, if raised, may dilute our <font color="blue">shareholders</font>’     <font color="blue">ownership interest</font> in us</td>
    </tr>
    <tr>
      <td>We may need to raise <font color="blue">additional</font> funds to develop or enhance our     <font color="blue">technologies</font>, to <font color="blue">fund expansion</font>, to respond to <font color="blue">competitive pressures</font> or to     acquire <font color="blue">complementary</font> products, <font color="blue">businesses</font> or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, our <font color="blue">total assets</font> were dlra111dtta8 million and our     <font color="blue">total liabilities</font> were dlra27dtta0 million</td>
    </tr>
    <tr>
      <td>As of the same date, our working     capital  was  dlra75dtta0 million  and our cash and <font color="blue">cash equivalents totaled</font>     dlra30dtta7 million</td>
    </tr>
    <tr>
      <td>Current and anticipated demand for our products as well as     <font color="blue">procurement</font> and production affect our need for capital</td>
    </tr>
    <tr>
      <td>Changes in these or     other factors could have a material <font color="blue">impact on</font> capital <font color="blue">requirements</font> and may     require us to raise <font color="blue">additional</font> capital</td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>      In 2005, except for <font color="blue">shares issued through</font> our Employee Stock Purchase     Plan and through the exercise of <font color="blue">stock option</font>s under our Incentive Stock     Option Plans, the only other capital raised was through the exercise of     warrants, which resulted in the issuance of 10cmam000 shares</td>
    </tr>
    <tr>
      <td>We anticipate that future changes in cash and working <font color="blue">capital will</font> be     <font color="blue">dependent</font> on a number of factors including:         •  Our ability to manage <font color="blue">effective</font>ly non-cash assets such as inventory and     <font color="blue">accounts receivable</font>;         •  Our ability to anticipate and adapt to the changes in our <font color="blue">industry such</font>     as new and <font color="blue">alternative medical procedures</font>;         •  Our level of <font color="blue">profitability</font>; and         •  Our <font color="blue">de<font color="blue">termination</font></font> to acquire or invest in products and <font color="blue">businesses</font>     <font color="blue">complementary</font> to ours</td>
    </tr>
    <tr>
      <td>We have <font color="blue">historically financed <font color="blue"><font color="blue">acquisition</font>s</font> using</font> our <font color="blue">existing cash</font>     resources</td>
    </tr>
    <tr>
      <td>While we believe our <font color="blue">existing cash</font> resources, including our bank     line of credit, will be sufficient to fund our operating needs for the next     twelve months, <font color="blue">additional</font> financing will may be required for our currently     envisioned long term needs</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">financing may</font> not be <font color="blue"><font color="blue">available on</font> terms</font> that are acceptable     to  us</td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> funds through the issuance of equity or     <font color="blue">convertible debt securities</font>, the <font color="blue">percentage ownership</font> of our <font color="blue">shareholders</font>     would be reduced and these <font color="blue">securities might</font> have rights, preferences and     <font color="blue">privileges senior</font> to those of our current <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font>     are not <font color="blue">available on</font> acceptable terms, our ability to fund our expansion,     take  advantage of <font color="blue">unanticipated opportunities</font>, develop or enhance our     products or services, or otherwise respond to <font color="blue">competitive pressures</font> would be     <font color="blue"><font color="blue">significant</font>ly</font> limited</td>
    </tr>
    <tr>
      <td>We  may  have  <font color="blue">difficult</font>y  sustaining <font color="blue">profitability</font> and may experience     <font color="blue">additional</font> losses in the future</td>
    </tr>
    <tr>
      <td>Although we <font color="blue">recorded net income</font> of dlra22dtta6 million, dlra14dtta7 million, and     dlra2dtta5 million for fiscal years 2005, 2004, and 2003 respectively, prior to     2002 we had <font color="blue">prolonged periods</font> of <font color="blue">consecutive quarterly net losses</font></td>
    </tr>
    <tr>
      <td>In order     to maintain and improve our <font color="blue">profitability</font>, we will need to continue to     <font color="blue">generate new sales while controlling</font> our costs</td>
    </tr>
    <tr>
      <td>However, any failure to do     so could harm our <font color="blue">profitability</font> and <font color="blue">negatively</font> affect the <font color="blue">market price</font> of     our stock</td>
    </tr>
    <tr>
      <td>We may be unable to respond to the <font color="blue">rapid technological</font> changes that often     affect the markets in which we compete</td>
    </tr>
    <tr>
      <td>If we fail to rapidly develop, <font color="blue">manufacture</font> and <font color="blue">market technologically</font>     <font color="blue">innovative products at</font> acceptable costs, our operating results will suffer</td>
    </tr>
    <tr>
      <td>We operate in an industry that is subject to <font color="blue">rapid technological</font>     change</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">remain competitive</font> and future operating results will     depend upon, among other things, our ability to anticipate and respond     rapidly  to  such  change  by  developing, <font color="blue">manufacturing</font> and marketing     <font color="blue">technologically innovative products</font> in <font color="blue">sufficient quantities at</font> acceptable     costs to <font color="blue">meet such demand</font></td>
    </tr>
    <tr>
      <td>As we introduce <font color="blue">new products</font> this may cause some     of  our  <font color="blue">existing products</font> to become obsolete, which may result in the     write-off of inventory</td>
    </tr>
    <tr>
      <td>However, without <font color="blue">new products</font> and <font color="blue">enhancements</font>, our     <font color="blue">existing products</font> will likely become obsolete due to <font color="blue">technological advances</font>     by other companies, <font color="blue">which could</font> result in the write-off of <font color="blue">inventory as well</font>     as  diminished  revenues</td>
    </tr>
    <tr>
      <td>Therefore,  we intend to continue to invest     <font color="blue">significant</font> amounts in research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">expenditures</font> for research and <font color="blue">development</font> were dlra7dtta9 million for     the year ended <font color="blue">December </font>31, 2005, dlra5dtta2 million in 2004 and, dlra4dtta4 million in     2003</td>
    </tr>
    <tr>
      <td>We anticipate that our ability to <font color="blue">compete will</font> require <font color="blue">significant</font>     research and <font color="blue">development</font> <font color="blue">expenditures</font> with a <font color="blue">continuing flow</font> of innovative,     high-quality  products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that we will be successful in     designing, <font color="blue">manufacturing</font> or <font color="blue">selling enhanced</font> or <font color="blue">new products</font> in a timely     manner</td>
    </tr>
    <tr>
      <td>Nor can we assure that a <font color="blue">competitor</font> could not introduce a new or     <font color="blue">enhanced product</font> or <font color="blue">technology</font> that could have an adverse effect on our     <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________    [77]Table of <font color="blue">Contents       </font>      Our <font color="blue">current research</font> and <font color="blue">development</font> programs are <font color="blue">directed toward</font> the     <font color="blue">development</font> of new <font color="blue">laser system</font>s and <font color="blue">delivery devices</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that     these <font color="blue">markets will</font> develop as anticipated or that our product <font color="blue">development</font>     <font color="blue">efforts will prove successful</font></td>
    </tr>
    <tr>
      <td>Nor can we assure that such <font color="blue">new products</font>, if     developed and introduced, will be <font color="blue">accepted by</font> the market</td>
    </tr>
    <tr>
      <td>We  may become a party to a patent <font color="blue">infringement</font> and other <font color="blue">intellectual</font>     property related actions or disputes, <font color="blue">which could</font> result in <font color="blue">significant</font>     royalty or other payments or in <font color="blue">injunctions</font> that can prevent the sale of our     products</td>
    </tr>
    <tr>
      <td>Our industry has been <font color="blue">characterized</font> by frequent allegations of patent     <font color="blue">infringement</font> and or other <font color="blue"><font color="blue">intellectual</font> property</font> related activity including     demands for licenses and <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitor</font>s or other <font color="blue">patent holders</font>     may assert that our products and the methods we employ are <font color="blue">covered by</font> their     patents</td>
    </tr>
    <tr>
      <td>In addition, we do not know whether our <font color="blue">competitor</font>s will apply for     and obtain patents that will prevent, limit or <font color="blue">interfere with</font> our ability to     make, use, sell or import our products</td>
    </tr>
    <tr>
      <td>Although we may seek to resolve any     potential  future  claims  or  actions, we may not be able to do so on     <font color="blue">reasonable terms</font>, or at all</td>
    </tr>
    <tr>
      <td>If, following a successful third-party action     for <font color="blue">infringement</font>, we cannot obtain a license or redesign our products, we     may have to stop <font color="blue">manufacturing</font> and marketing our products, and our business     <font color="blue">would suffer</font> as a result</td>
    </tr>
    <tr>
      <td>We <font color="blue">may become involved</font> in <font color="blue">litigation</font> not only as a result of alleged     <font color="blue">infringement</font> of a <font color="blue">third party</font>’s <font color="blue"><font color="blue">intellectual</font> property</font> rights but also to     protect our own <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>We have and <font color="blue">may hereafter become</font>     involved in <font color="blue">litigation</font> to protect the trademark rights <font color="blue">associated with</font> our     <font color="blue">company name</font> or the names of our products</td>
    </tr>
    <tr>
      <td>If we have to change the name of     our products, we may experience a loss in goodwill <font color="blue">associated with</font> customer     confusion and a loss of sales</td>
    </tr>
    <tr>
      <td><font color="blue">Infringement </font>and other <font color="blue"><font color="blue">intellectual</font> property</font> related claims, with or     <font color="blue">without merit</font>, can be expensive and time-consuming to litigate, and could     divert <font color="blue">management</font>’s attention from our core business</td>
    </tr>
    <tr>
      <td>We do not know whether     <font color="blue">necessary</font>  <font color="blue">licenses would</font> be available to us on satisfactory terms, or     whether we <font color="blue">could redesign</font> our products or processes to avoid <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>If  we  lose  this kind of <font color="blue">litigation</font>, a <font color="blue">court could</font> require us to pay     substantial damages, and prohibit us from using <font color="blue">technologies</font> essential to     our products, either of <font color="blue">which would</font> have a material adverse effect on our     business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue">divestitures</font> we make may not <font color="blue">provide us</font> the expected     benefits and <font color="blue">could disrupt</font> our business and harm our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">acquisition</font>s</font> we make may not <font color="blue">provide us</font> the expected benefits and     <font color="blue">could disrupt</font> our business and harm our <font color="blue">financial condition</font>, results of     <font color="blue">operations</font> and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>We have acquired <font color="blue">businesses</font> and <font color="blue">technologies</font> in     the past, and we <font color="blue">may continue</font> to acquire <font color="blue">businesses</font> or <font color="blue">technologies</font> that we     believe are a <font color="blue">strategic fit with</font> our business</td>
    </tr>
    <tr>
      <td>Any future <font color="blue"><font color="blue">acquisition</font>s</font> may     result in unforeseen operating <font color="blue">difficult</font>ies and <font color="blue">expenditures</font> and may absorb     <font color="blue">significant</font> <font color="blue">management</font> attention that <font color="blue">would otherwise</font> be available for     ongoing  <font color="blue">development</font>  of our business</td>
    </tr>
    <tr>
      <td>In addition, the integration of     <font color="blue"><font color="blue">acquisition</font> targets</font> may prove to be more <font color="blue">difficult</font> than expected, and we may     be <font color="blue">unsuccessful</font> in maintaining and developing <font color="blue">relations with</font> the employees,     customers and business partners and other <font color="blue"><font color="blue">acquisition</font> targets</font></td>
    </tr>
    <tr>
      <td>Since we will     not be able to <font color="blue">accurately predict</font> these <font color="blue">difficult</font>ies and <font color="blue">expenditures</font>, it is     possible that these <font color="blue">costs may outweigh</font> the value we realize from a future     <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>Future  <font color="blue"><font color="blue">acquisition</font>s</font> could result in issuances of equity     securities that would reduce our <font color="blue">shareholders</font>’ <font color="blue">ownership interest</font>, the     incurrence of debt, contingent liabilities, stock based compensation or     expenses related to the valuation of goodwill or other <font color="blue">intangible assets</font> and     the incurrence of large, immediate write-offs</td>
    </tr>
    <tr>
      <td>We may be unable to attract and retain <font color="blue">key personnel</font> who are critical to the     success of our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success also depends on</font> our ability to attract and retain     engineers  and  other <font color="blue">highly skilled personnel</font> and <font color="blue">senior managers</font></td>
    </tr>
    <tr>
      <td>In     addition, in order to meet our planned growth we must increase our sales     force,  both  domestic and <font color="blue">international</font>, with qualified employees and     personnel</td>
    </tr>
    <tr>
      <td>Hiring qualified                                         20       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>technical, sales and <font color="blue">management</font> personnel is <font color="blue">difficult</font> due to a limited     number of <font color="blue">qualified professionals</font> and <font color="blue">competition</font> in our industry for these     types of personnel</td>
    </tr>
    <tr>
      <td>We have in the past experienced delays and <font color="blue">difficult</font>ies     in recruiting and retaining <font color="blue">qualified technical</font> and <font color="blue">sales personnel</font> and     believe  that at times our personnel are <font color="blue">recruited <font color="blue">aggressive</font>ly by</font> our     <font color="blue">competitor</font>s and start-up companies</td>
    </tr>
    <tr>
      <td>Our employees are “at will” and may     leave our <font color="blue">employment at</font> any time</td>
    </tr>
    <tr>
      <td>As a result, we may experience <font color="blue">significant</font>     employee turnover</td>
    </tr>
    <tr>
      <td>Failure to attract and retain personnel, <font color="blue">particularly</font>     sales and technical personnel would make it <font color="blue">difficult</font> for us to develop and     market our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In addition, our business and <font color="blue">operations</font> are <font color="blue">substantially</font> <font color="blue">dependent</font>     on  the  performance  of our <font color="blue">key personnel</font>, including Eric Reuter, our     President  and Chief Executive Officer, Derek Bertocci, Vice President     Finance and Chief Financial Officer, Bob Mathews, Group Vice President,     Operations and Product Development, and Robert Mann, Group Vice President,     Global  Surgical Sales and Marketing</td>
    </tr>
    <tr>
      <td>We do not have <font color="blue">formal employment</font>     <font color="blue"><font color="blue">agreement</font>s</font>  with Messrs</td>
    </tr>
    <tr>
      <td>If such     <font color="blue">individuals</font> were to leave or become unable to perform services for our     company, our business could be <font color="blue">severely harmed</font></td>
    </tr>
    <tr>
      <td>Our quarterly operating results may fluctuate <font color="blue"><font color="blue">significant</font>ly</font> and any failure     to <font color="blue">meet financial expectations</font> for any <font color="blue">fiscal quarter may</font> cause our stock     price to decline</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">factors affect</font> our <font color="blue">quarterly financial</font> results including     the  timing of shipments and orders</td>
    </tr>
    <tr>
      <td>Our <font color="blue">laser products</font> are <font color="blue">relatively</font>     <font color="blue">expensive pieces</font> of <font color="blue">medical capital equipment</font> and the <font color="blue">precise shipment date</font>     of <font color="blue">specific units</font> can have a marked effect on our results of <font color="blue">operations</font> on a     <font color="blue">quarterly basis</font></td>
    </tr>
    <tr>
      <td>Additionally, our fiber optic <font color="blue">disposable delivery</font> devices     are <font color="blue">relatively</font> complex assemblies requiring <font color="blue">components</font> that can have long     <font color="blue">lead times</font></td>
    </tr>
    <tr>
      <td>Failure of suppliers to provide materials in a <font color="blue">timely manner</font> or     other  <font color="blue">disruptions</font>  in the <font color="blue">continuous production</font> of these <font color="blue">fiber optics</font>     <font color="blue">components</font>  could have a <font color="blue">substantially</font> marked effect on our results of     <font color="blue">operations</font> on a <font color="blue">quarterly basis</font></td>
    </tr>
    <tr>
      <td>Any delay in <font color="blue">product shipments</font> near the end     of a <font color="blue">quarter could</font> cause our quarterly results to fall short of anticipated     levels</td>
    </tr>
    <tr>
      <td>Furthermore, to the extent we receive orders near the end of a     quarter, we may not be able to fulfill the order during the balance of that     <font color="blue">same quarter</font></td>
    </tr>
    <tr>
      <td>Moreover, we typically receive a <font color="blue">disproportionate percentage</font>     of <font color="blue">orders toward</font> the end of <font color="blue">each quarter</font></td>
    </tr>
    <tr>
      <td>To the extent that we do not     receive anticipated orders or orders are delayed beyond the end of the     applicable  quarter,  our results may be <font color="blue"><font color="blue">adversely</font> affected</font> and may be     <font color="blue">unpredictable from quarter</font> to quarter</td>
    </tr>
    <tr>
      <td>In addition, because a <font color="blue">significant</font>     portion of our revenues in <font color="blue">each quarter</font> result <font color="blue">from orders</font> received in that     quarter, we base our production, inventory and operating <font color="blue">expenditure levels</font>     on anticipated <font color="blue">revenue levels</font></td>
    </tr>
    <tr>
      <td>Thus, if sales do not occur when expected,     <font color="blue">expenditure levels</font> could be <font color="blue">disproportionately high</font> and operating results     for  that  quarter and <font color="blue">potentially</font> future quarters, would be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We  <font color="blue">cannot assure</font> that we will accomplish <font color="blue">revenue growth</font> or     <font color="blue">profitability</font> on a quarterly or <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>Nor can we assure that revenue     growth or <font color="blue">profitability</font> will not fluctuate <font color="blue"><font color="blue">significant</font>ly</font> from quarter to     quarter</td>
    </tr>
    <tr>
      <td>If  we  are  unable  to  expand and maintain our <font color="blue"><font color="blue">relationship</font> with</font> our     US <font color="blue">distribution</font> partner, <font color="blue">Henry Schein </font>on favorable <font color="blue">contractual terms</font>, our     business may be harmed</td>
    </tr>
    <tr>
      <td>In July 2005, we <font color="blue">entered into</font> a non-exclusive <font color="blue">distribution</font> <font color="blue">agreement</font>     with <font color="blue">Henry Schein </font>(the “HSI Agreement”), pursuant to which Henry Schein, a     provider of healthcare products and services to office-based <font color="blue">practitioners</font>     <font color="blue">in the North American and European </font>markets, will distribute our aesthetic     <font color="blue">product line</font> to physicians and <font color="blue">physician practices within</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">The HSI Agreement </font>is terminable by either party upon 90 days notice</td>
    </tr>
    <tr>
      <td>The     Henry  Schein  <font color="blue">distribution</font>  <font color="blue">relationship</font>  is  intended to replace our     <font color="blue">distribution</font>  <font color="blue">relationship</font>  with  McKesson, which terminated <font color="blue">effective</font>     November 9, 2005</td>
    </tr>
    <tr>
      <td>McKesson had been our exclusive US <font color="blue">distribution</font> partner     for <font color="blue">aesthetic products</font> for <font color="blue">nearly four years until</font> April 2005, when our     <font color="blue"><font color="blue">relationship</font> with</font> McKesson was made non-exclusive</td>
    </tr>
    <tr>
      <td>On August 9, we received     a notice from McKesson that it intended to terminate the <font color="blue">McKesson Agreement     </font><font color="blue">effective</font> in November 2005</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>the <font color="blue">amendment</font> of our <font color="blue">distribution</font>     <font color="blue">agreement</font> with McKesson to make it non-exclusive and prior to <font color="blue">termination</font> of     the <font color="blue">distribution</font> <font color="blue"><font color="blue">relationship</font> with</font> McKesson, we experienced a <font color="blue">significant</font>     decline in sales of our <font color="blue">aesthetic products</font> through McKesson</td>
    </tr>
    <tr>
      <td>Sales of our     <font color="blue">aesthetic products</font> through the <font color="blue">Henry Schein </font>                                        21       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font><font color="blue">relationship</font> failed to offset the decline in <font color="blue">revenues through</font> McKesson in     the 2005</td>
    </tr>
    <tr>
      <td>A national <font color="blue">distribution</font> <font color="blue">relationship</font> that extends our reach is     important  to  our success because the <font color="blue">potential customer base</font> for our     aesthetic <font color="blue">product line</font> includes physicians from a variety of <font color="blue">specialties</font>     including among others, dermatologists, plastic surgeons, primary care and     OB/GYN physicians</td>
    </tr>
    <tr>
      <td>During the term of our <font color="blue">distribution</font> <font color="blue"><font color="blue">relationship</font> with</font>     McKesson, sales to McKesson accounted for a substantial portion of our     revenues</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, sales through McKesson     accounted for <font color="blue">approximately</font> 6prca of our <font color="blue">total revenues</font> and at <font color="blue">December </font>31,     2005 <font color="blue">accounts receivable</font> from McKesson accounted for <font color="blue">approximately</font> 1prca of our     total <font color="blue">accounts receivable</font></td>
    </tr>
    <tr>
      <td>Although we expect <font color="blue">revenue <font color="blue">generated through</font></font>     <font color="blue">Henry Schein </font>to increase <font color="blue"><font color="blue">significant</font>ly</font> as this new <font color="blue">distribution</font> <font color="blue">relationship</font>     is fully implemented, there can there be no assurance that our <font color="blue">distribution</font>     <font color="blue"><font color="blue">relationship</font> with</font> <font color="blue">Henry Schein </font><font color="blue">will adequately replace</font> our <font color="blue"><font color="blue">relationship</font> with</font>     McKesson and we may be unable to generate sufficient revenues on a timely     basis  or  at  all</td>
    </tr>
    <tr>
      <td>If we are unable to effect a timely and <font color="blue">effective</font>     transition to the new <font color="blue">distribution</font> <font color="blue">relationship</font> and maintain a favorable     <font color="blue">relationship</font>  with <font color="blue">Henry Schein </font>and/or another major US <font color="blue">distribution</font>     partner or if <font color="blue">Henry Schein </font>or any such other US <font color="blue">distribution</font> partner     encounters financial <font color="blue">difficult</font>ies, it could have a material adverse effect     on our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font>, and <font color="blue">future cash</font>     flows</td>
    </tr>
    <tr>
      <td>If we are unable to effect a <font color="blue">swift transition</font> and <font color="blue">rapidly establish</font> a strong     working <font color="blue"><font color="blue">relationship</font> with</font> our US <font color="blue">distribution</font> partner, Henry Schein, we     may be unable to achieve growth in sales of our aesthetic <font color="blue">product line</font> in a     <font color="blue">timely manner</font> or at all</td>
    </tr>
    <tr>
      <td>The <font color="blue">Henry Schein </font><font color="blue">distribution</font> <font color="blue">relationship</font> has replaced the McKesson     <font color="blue">distribution</font> <font color="blue">relationship</font> as our principal US <font color="blue">distribution</font> network for our     aesthetic  product  line,  but as of yet has not replaced the revenues     <font color="blue">previously</font>  <font color="blue">generated through</font> McKesson</td>
    </tr>
    <tr>
      <td>During 2004, sales to McKesson     accounted  for  <font color="blue">approximately</font>  23prca of our <font color="blue">total revenues</font>, and revenues     generated  through McKesson in 2005 declined</td>
    </tr>
    <tr>
      <td>Such <font color="blue">sales represented</font> a     material  portion of our revenues in 2004</td>
    </tr>
    <tr>
      <td>In 2005, revenues generated     through  <font color="blue">Henry Schein </font>failed to offset the decline in <font color="blue">revenues through</font>     McKesson</td>
    </tr>
    <tr>
      <td><font color="blue">Establishing </font>a strong US <font color="blue">distribution</font> partner for our aesthetic     products is important to our future success in the near future and beyond</td>
    </tr>
    <tr>
      <td>The  initial  phase of our <font color="blue">distribution</font> <font color="blue"><font color="blue">relationship</font> with</font> <font color="blue">Henry Schein </font>    involves  <font color="blue">significant</font>  training  and coordination <font color="blue">activities</font> which are     <font color="blue">necessary</font> to achieve a successful <font color="blue">distribution</font> partnership</td>
    </tr>
    <tr>
      <td>Although to date     we have made substantial progress in <font color="blue">effecting</font> this transition, unless we     are able to <font color="blue">accelerate</font> this process and expand our <font color="blue">relationship</font> rapidly we     will be unable to generate revenues sufficient to replace those <font color="blue">previously</font>     <font color="blue">generated through</font> our <font color="blue"><font color="blue">relationship</font> with</font> McKesson</td>
    </tr>
    <tr>
      <td>If our <font color="blue">products contain defects</font> that harm our customers’ patients, it would     damage our reputation, subject us to <font color="blue">potential legal liability</font> and cause us     to <font color="blue">lose customers</font> and revenue</td>
    </tr>
    <tr>
      <td>Laser systems and <font color="blue"><font color="blue">fiber <font color="blue">optic delivery</font></font> devices</font> are inherently complex     in  design  and  <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>Laser systems require <font color="blue">ongoing regular</font>     maintenance</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of our lasers, <font color="blue">laser products</font>, disposable     <font color="blue">delivery devices</font>, and <font color="blue">systems involve highly complex</font> and <font color="blue">precise processes</font></td>
    </tr>
    <tr>
      <td>As a result of the <font color="blue">technical complexity</font> of our products, changes in our or     our suppliers’ <font color="blue">manufacturing</font> processes or the <font color="blue">inadvertent use</font> of defective     materials by us or our <font color="blue">suppliers could</font> result in a material adverse effect     on  our ability to achieve acceptable <font color="blue">manufacturing</font> yields and product     <font color="blue">reliability</font></td>
    </tr>
    <tr>
      <td>To the extent that we do not achieve such yields or product     <font color="blue">reliability</font>, this could have a material affect on our business, financial     position, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">customers may discover defects</font> in our products after the products     have <font color="blue">been fully deployed</font> and operated <font color="blue">under peak stress conditions</font></td>
    </tr>
    <tr>
      <td>In     addition,  some  of our products are <font color="blue">combined with products from</font> other     vendors, which may contain defects</td>
    </tr>
    <tr>
      <td>As a result, should problems occur, it     may be <font color="blue">difficult</font> to identify the source of the problem</td>
    </tr>
    <tr>
      <td>If we are unable to     fix defects or other problems, we could experience, among other things:         •  loss of customers;         •  <font color="blue">increased costs</font> of product, returns and <font color="blue">warranty expenses</font>;         •  damage to our brand reputation;                                         22       _________________________________________________________________    [80]Table of <font color="blue">Contents       </font>  •  failure to <font color="blue">attract new customers</font> or achieve market <font color="blue">acceptance</font>;         •  action by <font color="blue">regulatory</font> authorities;         •  diversion of <font color="blue">development</font> and <font color="blue">engineering resources</font>; and         •  <font color="blue">legal actions by</font> our customers</td>
    </tr>
    <tr>
      <td>The occurrence of any one or more of the <font color="blue">foregoing factors could</font>     <font color="blue">seriously harm</font> our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our financial results and stock price are <font color="blue">affected by</font> a number of factors     which are beyond our control</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">factors affect</font> our financial results and stock price     including, but not limited to:         •  product mix;         •  <font color="blue">competitive pricing pressures</font>;         •  material costs;         •  revenue and expenses related to <font color="blue">new products</font> and <font color="blue">enhancements</font> to     <font color="blue">existing products</font>;         •  delays in <font color="blue">customer purchases</font> in <font color="blue">anticipation</font> of <font color="blue">new products</font> or product     <font color="blue">enhancements</font> by <font color="blue">Laserscope </font>or its <font color="blue">competitor</font>s; and         •  the risk of loss or <font color="blue">interruption</font> to our <font color="blue">operations</font> or <font color="blue">increased costs</font>     due to <font color="blue">earthquakes</font>, the <font color="blue">availability</font> of power and energy supplies and other     <font color="blue">events beyond</font> our control</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has <font color="blue">historically been</font> subject to     <font color="blue">significant</font> fluctuations</td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations may</font> be due to <font color="blue">factors specific</font>     to Laserscope, such as:         •  <font color="blue">quarterly fluctuations</font> in our financial results;         •  changes in analysts’ estimates of future results;         •  changes in investors’ <font color="blue">perception</font>s of our products;         •  <font color="blue">announcement</font> of new or <font color="blue">enhanced product</font>s by us or our <font color="blue">competitor</font>s;         •  <font color="blue">announcement</font>s relating to <font color="blue"><font color="blue">acquisition</font>s</font> and <font color="blue">strategic transactions by us</font>     or our <font color="blue">competitor</font>s;         •  <font color="blue">general conditions</font> in the <font color="blue">medical equipment industry</font>; and         •  <font color="blue">general conditions</font> in the <font color="blue">financial markets</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market</font> has from time to time experienced <font color="blue">extreme price</font> and     volume fluctuations, <font color="blue">particularly</font> among stocks of high <font color="blue">technology</font> companies,     which, on occasion, have <font color="blue">been unrelated</font> to the operating performance of     <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>Factors not directly related to our performance, such     <font color="blue">as negative industry</font> reports or disappointing earnings <font color="blue">announcement</font>s by     publicly traded <font color="blue">competitor</font>s, may have an <font color="blue">adverse <font color="blue">impact on</font></font> the <font color="blue">market price</font>     of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had 22cmam296cmam689 shares of outstanding     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The sale of a substantial number of shares of <font color="blue">common stock</font> or     the  <font color="blue">perception</font>  that  such  <font color="blue">sales could</font> occur, could <font color="blue">adversely</font> affect     prevailing <font color="blue">market price</font>s for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our financial results and stock price are highly <font color="blue">dependent</font> upon successful     pricing and sales of our main <font color="blue">product line</font>, the <font color="blue">GreenLight </font><font color="blue">laser system</font> and     related <font color="blue">fiber <font color="blue">optic delivery</font></font> device, <font color="blue">which increases</font> our <font color="blue">vulnerability</font> to a     variety of <font color="blue">factors outside</font> of our <font color="blue">direct control</font></td>
    </tr>
    <tr>
      <td>Our financial results are highly <font color="blue">dependent</font> on successful pricing and     sales of the <font color="blue">GreenLight </font>PV <font color="blue">laser system</font> and related <font color="blue">fiber <font color="blue">optic delivery</font></font>     device</td>
    </tr>
    <tr>
      <td>Pricing and sales may be <font color="blue">affected by</font> a myriad of factors including     public and private payer <font color="blue">reimbursement</font> <font color="blue">domestically</font> and <font color="blue"><font color="blue">international</font>ly</font>,     products  and  services  offered by <font color="blue">competitor</font>s with greater financial     resources than us who may engage in <font color="blue">aggressive</font> marketing                                         23       _________________________________________________________________    [81]Table of <font color="blue">Contents       </font>and pricing strategies, new <font color="blue">technologies</font> that deliver superior results to     PVP or comparable results at <font color="blue">commensurate</font> or lower costs, our ability to     maintain or reduce the costs of materials and <font color="blue"><font color="blue">components</font> used</font> to produce the     <font color="blue">GreenLight </font>products, among other <font color="blue">factors beyond</font> our <font color="blue">direct control</font></td>
    </tr>
    <tr>
      <td>Any of     these or other <font color="blue">factors could compel us</font> to make <font color="blue">significant</font> reductions in our     pricing or other changes in our sales strategy, <font color="blue">which could</font> <font color="blue">adversely</font> affect     our <font color="blue">financial performance</font> and <font color="blue">future prospects</font></td>
    </tr>
    <tr>
      <td>We  are a party to <font color="blue">legal proceedings</font> arising in the <font color="blue">ordinary course</font> of     business</td>
    </tr>
    <tr>
      <td>We are party to a number of <font color="blue">legal proceedings</font> arising in the ordinary     course of business</td>
    </tr>
    <tr>
      <td>While it is not feasible to predict or determine the     outcome of the actions <font color="blue">brought against us</font>, we believe that the ultimate     resolution of these claims will not ultimately have a material adverse     effect on our <font color="blue">financial position</font>, results of <font color="blue">operations</font>, or <font color="blue">future cash</font>     flows</td>
    </tr>
    <tr>
      <td>We typically assume warranty <font color="blue">obligations</font> in <font color="blue">connection with</font> the sales of our     products, <font color="blue">which could</font> cause a <font color="blue">significant</font> drain on our resources if our     products perform poorly</td>
    </tr>
    <tr>
      <td>We have a <font color="blue">direct field service organization</font> that <font color="blue">provides service</font> for     our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> provide a <font color="blue">twelve month warranty on</font> our laser     systems</td>
    </tr>
    <tr>
      <td>Our warranties and     <font color="blue">premium <font color="blue">service contract</font>s provide</font> for a “99dtta0prca Uptime Guarantee” on our     <font color="blue">laser system</font>s</td>
    </tr>
    <tr>
      <td>Under provisions of this guarantee, at the request of the     customer, we extend the term of the related warranty or <font color="blue">service contract</font> if     <font color="blue">specified system uptime levels</font> are not maintained</td>
    </tr>
    <tr>
      <td>Although the number of     warranties extended under this program are currently not material, we can     not assure that the number of warranties will not become <font color="blue">significant</font> in the     future if our products perform poorly, <font color="blue">which could</font> cause a <font color="blue">significant</font> drain     on our resources</td>
    </tr>
    <tr>
      <td>Natural catastrophic events, such as <font color="blue">earthquakes</font>, hurricanes or terrorist     <font color="blue">attacks may reduce</font> our revenues and harm our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">corporate headquarters</font>, including our research and <font color="blue">development</font>     <font color="blue">operations</font>, our <font color="blue">manufacturing</font> <font color="blue">facilities</font>, and our principal sales, marketing     and <font color="blue">service offices</font>, are located in the <font color="blue">Silicon Valley </font>area of Northern     California, a region known for seismic activity</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> natural     disaster, such as an earthquake or a flood, could have a material adverse     <font color="blue">impact on</font> our business, operating results, and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>In     addition, despite our <font color="blue">implementation</font> of <font color="blue">network security measures</font>, our     servers  are  vulnerable  to  computer viruses, break-ins, and similar     <font color="blue">disruptions</font> from unauthorized tampering with our <font color="blue">computer systems</font></td>
    </tr>
    <tr>
      <td>Any such     event  could have a material adverse effect on our business, operating     results, and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>In addition, as our business has grown, we have <font color="blue">become increasingly</font>     subject to the risks arising <font color="blue">from adverse</font> changes in domestic and global     economic conditions, natural and man-made disasters</td>
    </tr>
    <tr>
      <td><font color="blue">Disruptions </font>in large     areas of the <font color="blue"><font color="blue">United States</font> </font>due to <font color="blue">natural disasters</font> and <font color="blue">subsequent relief</font>     efforts, as seen with the hurricanes that struck the southern <font color="blue"><font color="blue">United States</font> </font>    in the summer and fall of 2005, could have a material adverse effect on our     business, operating results, and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The effects of war or     acts of <font color="blue">terrorism could likewise</font> have a material adverse effect on our     business, operating results, and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">terrorist attacks</font>     in  New  York, Pennsylvania and Washington, DC on <font color="blue">September </font>11, 2001     <font color="blue">disrupted commerce throughout</font> the world and intensified the <font color="blue">uncertainty</font> of     the <font color="blue"><font color="blue">United States</font> </font>and other economies</td>
    </tr>
    <tr>
      <td>The <font color="blue">continued threat</font> of terrorism and     <font color="blue">heightened security</font> and <font color="blue">military action</font> in response to this threat, or any     future acts of terrorism, may cause further <font color="blue">disruptions</font> to these economies     and create <font color="blue">further <font color="blue">uncertainties</font></font></td>
    </tr>
    <tr>
      <td>To the extent that such <font color="blue">disruptions</font> or     <font color="blue">uncertainties</font> result in delays or <font color="blue">cancellations</font> of customer orders, or the     <font color="blue">manufacture</font> or shipment of our products, our business, operating results,     financial  condition  and <font color="blue">cash flows</font> could be <font color="blue">materially</font> and <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We have <font color="blue">never paid cash <font color="blue">dividends on</font></font> our <font color="blue">common stock</font> and do not     anticipate <font color="blue">paying cash <font color="blue">dividends on</font></font> the <font color="blue">common stock</font> in the foreseeable     future</td>
    </tr>
    <tr>
      <td>The payment of <font color="blue">dividends on</font> the <font color="blue">common stock</font> <font color="blue">will depend on</font> our     earnings,  <font color="blue">financial condition</font> and other business and <font color="blue">economic factors</font>     <font color="blue">affecting us at such</font> time as the <font color="blue">Board of Directors </font>may consider relevant</td>
    </tr>
    <tr>
      <td>The exercise of <font color="blue">outstanding options</font> and <font color="blue">warrants <font color="blue">granted under</font></font> our stock     option plans and other options and <font color="blue">warrants may</font> result in dilution of our     <font color="blue">shareholders</font> equity interests</td>
    </tr>
    <tr>
      <td><font color="blue">Shareholders </font>may experience dilution in the <font color="blue">net tangible book value</font> of     their <font color="blue">investment upon</font> the exercise of <font color="blue">outstanding options</font> and warrants     <font color="blue">granted under</font> our <font color="blue">stock option</font> plans and other options and warrants</td>
    </tr>
    <tr>
      <td><font color="blue">Other Risks</font></td>
    </tr>
    <tr>
      <td>Other risks are <font color="blue">detailed from</font> time to time in our <font color="blue">press releases</font> and     other  <font color="blue">public disclosure filings with</font> the <font color="blue"><font color="blue">United States</font> </font>Securities and     Exchange Commission (“SEC”), copies of which are <font color="blue">available upon request from</font>     us</td>
    </tr>
  </tbody>
</table>